"Twice-a-month" clodronate 200 mg IM: A new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis

Advances in Therapy

Volumn 27, Issue 5, 2010, Pages 314-320

  Muratore, M ^a   Quarta, L ^a   Calcagnile, F ^a   Quarta, E ^a  

^a Hospital Galateo   (Italy)

Author keywords

Adherence; Bisphosphonates; Clodronate; Dosing regimen; Postmenopausal osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; OSTEOCALCIN; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE PAIN; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR; HUMAN; INJECTION SITE PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NURSING COST; OSTEOLYSIS; PAIN ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT REFUSAL; VISUAL ANALOG SCALE; WOMEN'S HEALTH; DRUG ADMINISTRATION; DRUG EFFECTS; LUMBAR VERTEBRA; MEDICATION COMPLIANCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CLODRONIC ACID; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN;

EID: 77956227568     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0027-4     Document Type: Article

References (37)

1. Kanis JA. Osteoporosis. Cambridge University Press, USA. 1999.
2. Nguyen ND, Eisman JA, Center JR, Nguyen TV. Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab. 2007;92:955-962.
3. Cooper C. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol. 1993;7:459-477.
4. Strader C, Shinoff CW, Anthony MS, Fitzpatrick LA. Burden of hip and wrist fractures: Incidence estimates of non-traumatic fractures in older women and men in North America, Western Europe, Australia, and Japan. ASBMR 29th Annual Meeting, Honolulu, Hawaii, 2007 September 16-20:M349. Available at: Http:// www.abstractsonline.com/viewer/viewAbstract.asp? CKey={8755EAC5-CCF1- 4FC5-90EB-6FD3D9ED7914} &MKey={07E476EC-41FE-4031-A4C7-AAAB51BD8DB8} &AKey={D0C01D4F-E23B-45E2-ACD4-0AF8AC866B8B} &SKey={673883CC-97BC-4339- 917A-D60CFA24B90D}. Last accessed: April 26, 2010.
5. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.
6. Badamgarav E, Fitzpatrick LA. A new look at osteoporosis outcomes: The influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc. 2006;81:1009-1012.
7. Adachi J, Lynch N, Middelhoven H, et al. The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review. BMC Musculoskelet Disord. 2007;8:97.
8. Fleisch H. Bisphosphonates in bone diseases. Academic Press, USA. 2000.
9. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: A database analysis study. Curr Med Res Opin. 2006;22:1757-1764.
10. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19:511-517.
11. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493-1501.
12. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17:914-921.
13. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008;24:1337-1344.
14. Ghinoi V, Brandi ML. Clodronate: Mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother. 2002;3:1643-1656.
15. Kanis JA, McCloskey EV, Sirtori P, et al. Rationale for the use of clodronate in osteoporosis. Osteoporos Int. 1993;3[Suppl. 2]:23-28.
16. Frediani B, Cavalieri L, Cremonesi G. Clodronic acid formulations available in Europe and their use in osteoporosis: A review. Clin Drug Investig. 2009;29:359-379.
17. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-759.
18. Rossini M, Braga V, Gatti D, et al. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone. 1999;24:125-129.
19. Filipponi P, Cristallini S, Policani G, et al. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass. Bone. 2000;26:269-274.
20. Del Puente A, Scognamiglio A, Itto E, et al. Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. J Rheumatol. 2000;27:1980-1983.
21. Sartori L, Adami S, Filipponi P, Crepaldi G. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging Clin Exp Res. 2003;15:271-283.
22. McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: Results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res. 2004;19:728-736.
23. McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: Results of a double-blind, placebocontrolled randomized study. J Bone Miner Res. 2007;22:135-141.
24. Frediani B, Falsetti P, Baldi F, et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: Evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone. 2003;33:575-581.
25. Poli G, Mariotti F, Corrado ME, Acerbi D. A tolerability and pharmacokinetic study of a new injectable formulation of disodium clodronate in healthy female volunteers. Eur J Drug Metab Pharmacokinet. 2004;29:145-152.
26. Rovetta G, Monteforte P, Balestra V. Intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res. 2000;26:25-30.
27. Rossini M, Viapiana O, Ramonda R, et al. Intraarticular clodronate for the treatment of knee osteoarthritis: Dose ranging study vs hyaluronic acid. Rheumatology. 2009; 48:773-778.
28. Ceponis A, Waris E, Mönkkönen J, et al. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum. 2001;44:1908-1916.
29. Van Lent PL, Holthuysen AE, Van Rooijen N, Van De Putte LB, Van Den Berg WB. Local removal of phagocytic synovial lining cells by clodronateliposomes decreases cartilage destruction during collagen type II arthritis. Ann Rheum Dis. 1998;57:408-413.
30. McGuire MKB, Russel RGG, Murphy G, Reynolds JJ. Diphosphonates inhibit production of prostaglandin and collagen as by human cells in vitro. Ann Rheum Dis. 1981;40:515-529. [Notes from Heberden Society: Clinical Meeting 1981, page 515]
31. Teronen O, Konttinen YT, Lindqvist C, et al. Inhibition of matrix metalloproteinases-1 by dichloromethylene bisphosphonate. Calcif Tissue Int. 1997;61:59-61.
32. Osterman T, Kippo K, Laurén L, et al. A comparison of clodronate and indomethacin in the treatment of adjuvant arthritis. Inflamm Res. 1997;46:79-85.
33. Itoh F, Aoyagi S, Kusama H, et al. Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation. 2004;28:15-21.
34. Gomez-Barrena E, Lindroos L, Ceponis A, et al. Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clin Exp Rheumatol. 2006;24:622-628.
35. Barrera P, Blom A, van Lent PL, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 2000;43:1951-1959.
36. van Rooijen N, van Kesteren-Hendrikx E. Clodronate liposomes: Perspectives in research and therapeutics. J Liposome Res. 2002;12:81-94.
37. Frith JC, Mönkkönen J, Auriola S, et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001;44:2201-2210.